Dexfenfluramine hydrochloride: An anorexigenic agent

American Journal of Health-System Pharmacy

Volumn 54, Issue 18, 1997, Pages 2059-2072

  Bever, Kristine A ^a   Perry, Paul J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Anorexics; Dexfenfluramine hydrochloride; Dosage; Metabolism; Obesity; Pharmacokinetics; Toxicity

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; SEROTONIN AGONIST;

CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; EATING HABIT; HEADACHE; HUMAN; INSOMNIA; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0030852548     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.18.2059     Document Type: Review

References (65)

1. Silverstone T. Appetite suppressants: a review. Drugs. 1992; 43:820-36.
2. Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr. 1992; 55(suppl):203-5.
3. Olin BR, Hebel SK, Dewein AC et al., eds. Drug facts and comparisons. St. Louis: Facts and Comparisons; 1996.
4. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr. 1992; 55:181S-4S.
5. Weintraub M, Hasday JD, Mushlin AL et al. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984; 144:1143-8.
6. Weintraub M, Sundaresan PR, Madan M et al. Long-term weight control study. Clin Pharmacol Ther. 1992; 51:581-646.
7. Redux package insert. Lexington, MA: Wyeth-Ayerst Company; 1996 Apr.
8. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992; 43:713-33.
9. Wurtman JJ. Carbohydrate cravings: a disorder of food intake and mood. Clin Neuropharmacol. 1988; 11(suppl 1):139-45.
10. Blundell JE, Lawton CL. Serotonin and dietary fat intake: effects of dexfenfluramine. Metabolism. 1995; 44:33-7.
11. Bjorntorp P. Neuroendocrine abnormalities in human obesity. Metabolism. 1995;44(suppl 2):38-41.
12. Review and evaluation of clinical data. New drug application. Dexfenfluramine application summary. Rockville, MD: Food and Drug Administration; 1996. [Obtained through the Freedom of Information Act.]
13. Gross AS, Phillips AC, Rieutord A et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol. 1996; 41:311-7.
14. Caccia S, Conforti I, Duchier J et al. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D-and DL-fenfluramine for 15 days. Em J Clin Pharmacol. 1985; 29:221-4.
15. Cheymol G, Weissenburger J, Poirier JM et al. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol. 1995; 39:684-7.
16. Bremer JM, Scott RS, Lintott CJ. Dexfenfluramine reduces cardiovascular risk factors. Int J Obes. 1994; 18:199-203.
17. Lafreniere F, Lambert J, Rasio E et al. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. Int J Obes. 1993; 17:25-30.
18. Breum L, Pedersen JK, Ahlstrom F et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-center trial in general practice. Int J Obes. 1994; 18:99-103.
19. Finer N. Body weight evolution during dexfenfluramine treatment after initial weight control. Int J Obes. 1992; 16(suppl):25-9.
20. O'Connor H, Richman RM, Steinbeck KS et al. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int J Obes. 1995; 19:181-9.
21. Mathus-Vliegen EMH. Prolonged surveillance of dexfenfluramine in severe obesity. Neth J Med. 1993; 43:246-53.
22. Mathus-Vliegen EMH, Van De Voorde K, Kok AME et al. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behavior. J Intern Med. 1992; 232:119-27.
23. Guy-Grand B, Apfelbaum M, Crepaldi G et al. International trial of long-term dexfenfluramine in obesity. Lancet. 1989; 2:1142-5.
24. Pfohl M, Luft D, Blomberg I et al. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes. 1994; 18:391-5.
25. Storlien LH, Thorburn AW, Smythe GA et al. Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats. Diabetes. 1989; 38:499-503.
26. Proietto J, Thorburn AW, Fabris S et al. Effects of dexfenfluramine on glucose turnover in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract. 1994; 23:127-34.
27. Willey KA, Molyneaux LM, Yue DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycemic control. Diabet Med. 1994; 11:701-4.
28. Greco AV, Mingrone E, Capristo E et al. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Metabolism. 1995; 44(suppl 2):57-61.
29. Stewart GO, Stein GR, Davis TME et al. Dexfenfluramine in type II diabetics: effect on weight and diabetes control. Med J Aust. 1993; 158:167-9.
30. Russell GM, Checkley SA, Feldman J et al. A controlled trial of d-fenfluramine in bulimia nervosa. Clin Neuropharmacol. 1988; 11(suppl 1):146-59.
31. Asberg M, Perris C, Schalling D et al. The CPRS-development and application of a psychiatric rating scale. Acta Psychiatr Scand. 1978; 271(suppl):5-27.
32. Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71.
33. Garner DM, Garfinkel PE. The Eating Attitudes Test: an index of the symptoms of anorexia nervosa. Psychol Med. 1979; 9:273-9.
34. Stunkard A, Berkowitz R, Tanrikut C et al. d-Fenfluramine treatment of binge eating disorder. Am J Psychiatry. 1996; 153:1455-9.
35. Gormally J, Black S, Daston S et al. The assessment of binge eating severity among obese persons. Addict Behav. 1982; 7:47-55.
36. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985; 29:71-83.
37. O'Rourke D, Wurtman JJ, Wurtman RJ et al. Treatment of seasonal depression with d-fenfluramine. J Clin Psychiatry. 1989; 50:343-7.
38. Hamilton M. Development of a rating scale for primary depressive illness. Br J Clin Psychol. 1967; 6:278-96.
39. Rosenthal N, Hefferman M. Bulimia, carbohydrate craving and depression: a central connection? In: Wurtman RJ, Wurtman JJ, eds. Nutrition and the brain. Vol. 7. New York: Raven; 1986:139-66.
40. Spring B, Wurtman J, Wurtman R et al. Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr. 1995; 62:1181-7.
41. Fagerström K-O. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978; 3:235-41.
42. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs. 1977; 14:260-82.
43. Shader RI, DiMascio A, eds. Psychotropic drug side effects: clinical and theoretical perspectives. Baltimore: Williams & Wilkins; 1970:4-9,63-85,92-106,116-23,149-98.
44. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976; 33:279-86.
45. Goodall E, Oxtoby C, Richards R et al. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry. 1988; 153:208-13.
46. Brzenzinski AA, Wurtman J, Wurtman RJ et al. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol. 1990; 76:296-301.
47. Chaplin S. Adverse effects of drugs used for weight reduction. Adverse Drug React Bull. 1991; 148:556-9.
48. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol. 1995; 75:51A-4A.
49. D'Arcy PF. Warnings from the UK Committee on Safety of Medicines: pulmonary hypertension with fenfluramine and dexfenfluramine. Int J Pharm. 1992; 6:217-8.
50. Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996; 335:609-16.
51. Cacoub P, Dorent R, Nataf P et al. Pulmonary hypertension and dexfenfluramine. Eur J Clin Pharmacol. 1995; 48:81-3. Letter.
52. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol. 1995; 75:63A-6A.
53. Braun D, Trechot P, Netter P et al. Recurrent interstitial pneumonitis and dexfenfluramine. Chest. 1993; 103:1927. Letter.
54. Kleven MS, Seiden LS. D-, L-, DL-fenfluramine cause long lasting depletions of serotonin in rat brain. Brain Res. 1989; 505:351-3.
55. McCann U, Hatzidimitriou G, Ridenour A et al. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther. 1994; 269:792-8.
56. Mills KC. Serotonin syndrome. Am Fam Physician. 1995; 52:1475-82.
57. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995; 29:619-24.
58. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22:1-21.
59. Harvey A, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin re-uptake inhibitors. Part I. J Clin Psychopharmacol. 1996; 16:273-85.
60. Harvey A, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996; 16:345-55.
61. Stunkard AJ. Minireview: anorectic agents lower a body weight set point. Life Sci. 1982; 30:2043-55.
62. Weintraub M, Rubio A, Golik A et al. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther. 1991; 50:330-7.
63. FDC Rep. 1996; 58(Nov 18):T&G 5-7.
64. Red book update. 1996; 16(Jan):57,58,61.
65. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. Mayo Clinic World Wide Web site. URL: http://www.mayo.edu/news/ mayo%20Rochester/1997/07.Jul.97/fenphen/Fenphenms. html. Accessed 1997 Jul 7.